Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 13/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3743288 | 0.79 | CCR2 (0.61) | CCR2HTTCCR1CCR5CXCR4 | |
| SCHEMBL13483780 | 0.75 | CCR2 (0.55) | CCR2HTTRAB9ACCR1CCR5 | |
| SCHEMBL12799205 | 0.75 | CCR2 (0.55) | CCR2HTTRAB9ACCR1CCR5 | |
| SCHEMBL3742895 | 0.74 | CCR2 (0.56) | CCR2HTTRAB9AMMP1 | |
| SCHEMBL3215740 | 0.73 | CCR2 (0.50) | CCR2RAB9AALDH1A1 | |
| SCHEMBL1877899 | 0.72 | ALDH1A1 (0.51) | RAB9AALDH1A1 | |
| SCHEMBL1876072 | 0.72 | ALDH1A1 (0.51) | RAB9AALDH1A1 | |
| SCHEMBL29346025 | 0.72 | HTT (0.69) | CCR2HTTRAB9AALDH1A1CCR1 | |
| SCHEMBL3748736 | 0.71 | CA1 (0.36) | HTTALDH1A1 | |
| SCHEMBL14010728 | 0.71 | CCR2 (0.54) | CCR2HTTRAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497261-B2 | 3-aminocaprolactam compounds for treating inflammatory disorders | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2013-07-30 | — | — | US | claimed |
| US-20100292213-A1 | Anti-Inflammatory Agents | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2010-11-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292213-A1 | Anti-Inflammatory Agents | TNF, IL1RN, IL1R1 | CCR2 121/4885HTT 3616/4885RAB9A 2291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.